Today is your last chance to participate in a focus group study using your smart phones. Amazon gift cards will be given to all who participate. Contact Kristin Mraz,Community Recruitment Manager - WEGO Health, 177 Tremont Street, 3rd Floor,Boston, MA,02111 - cell: 518.774.6114 - office: 617.863.7745 - fax: 617.426.5027 - email@example.com. I've worked with these
This small but hopefully important story snuck by me at this year's American Society of Clinical Oncology (ASCO) meetings earlier this month; an obscure study about a new class of anti-myeloma drugs. I blogged about it after ASH in San Francisco last December, asking if "This could be the new blockbuster therapy we are waiting
Renowned Tweeter, Cindy from New Jersey, @Myeloma Teacher, passed along Dr. Vincent Rajkumar's Top Seven myeloma-related abstracts from this year's American Society of Clinical Oncology annual meetings in Chicago: Top 7 #ASCO15 #Myeloma Abstracts - @VincentRK 7- Panorama - http://abstracts.asco.org/156/AbstView_156_146520.h tml 6- Elo- Vd vs Vd - http://abstracts.asco.org/156/AbstView_156_144027.h tml 5- CHAMPION - http://abstracts.asco.org/156/AbstView_156_147850.html 4-CALGB Len
Reports about the promising and innovative new myeloma therapy, ARRY-520 (filanesib), were conspicuously absent at this year's American Society of Clinical Oncology (ASCO) meetings this year in Chicago. Many myeloma specialists are hopeful that filanesib will match or even exceed the headline making results revealed for daratumumab at this year's annual event. Yet the only
I'm still hoping for some significant myeloma related data to emerge as the American Society of Clinical Oncology (ASCO) meetings wide down in Chicago. In the meantime, the Myeloma Beacon did a nice job reviewing several poster studies which focused on my genetic abnormality: an 11;14 translocation I developed after my first stem cell transplant.
As expected, general oncology news is overwhelming myeloma updates at this year's American Society of Clinical Oncology (ASCO) meetings in Chicago. Emerging themes are dominated by success among several immunotherapies and biologics used to battle advanced melanoma (skin cancer), a number of other solid tumor cancer types and soft tissue sarcomas. The overriding mainstream media
Looks like daratumumab is going to deliver as promised. It's strengths: minimal side effects and close to 30% effectiveness as a stand along agent in heavily pretreated patients. Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients Results from the Phase 2
With so much going on in my myeloma world, I almost forgot about the American Society of Clinical Oncology (ASCO) annual meeting in Chicago early next month. I'm not going this year. But I'll have my ear-to-the-ground and pass along any big news. Speaking of "big," ASCO is the largest oncology conference in the world.
It is so sad to hear that Arnie has passed away. We met him briefly at your beach party, and I am sorry now that I didn't take the time to visit longer. I think back when I was first diagnosed, and I became somewhat familiar with the regulars who posted here almost five years
I have written a lot about SAR650984 recently. SAR is an anti-CD38 monoclonal antibody. Myeloma specialist, Dr. Thomas Martin, calls it "Along with daratumumab, the next blockbuster drug for myeloma. Here's an introduction to a helpful, five minute video produced by our friends at Patient Power during ASCO: Myeloma Research Progress: Anti-CD38 Monoclonal Antibodies in
Disappointed with limited of myeloma related news trickling out of Chicago last week? You shouldn't be. True, there wasn't a lot of new data presented at this year's American Society of Clinical Oncology (ASCO) meetings. But some was significant. And more will be available June 12th - 15th at the European Hematology Association (EHA) conference
I'll spend the next few days sharing and interpreting data from the American Society of Clinical Oncology (ASCO) annual meetings at McCormick Place on Chicago's waterfront. But why reinvent the wheel? The MMRF has done an excellent job reporting on ASCO thus far. The excerpt I have posted below focuses on relapsed/refractory patients. But there
Today is myeloma day at the American Society of Clinical Oncology annual meetings in Chicago. There isn't a lot of myeloma related data being presented this year, but the important stuff is out today. Normally I'd be there covering the event. Not this year. I spent today at Mayo Clinic in Jacksonville, Florida. Just finishing
As I mentioned earlier this week, there isn't much myeloma related activity at the American Society of Clinical Oncology (ASCO) until Monday. That gives us a chance to review a couple of important things to look for when comparing one experimental therapy to another. Let's start with relapsed/refractory. Someone who relapses isn't necessarily refractory (resistant)
Normal 0 false false false EN-US X-NONE X-NONE MicrosoftInternetExplorer4 Walter Capone, President of the Multiple Myeloma Research Foundation (MMRF), is excited about a new myeloma therapy: SAR650984. He mentioned this exciting new therapeutic option for heavily pretreated multiple myeloma patients while we were working together in Tampa two weeks ago. Here's the MMRF's press release
It's ASCO weekend in Chicago. For the first time in five years I'm not there; the timing with our move wasn't good. So I will be covering it from our new home in Fernandina Beach near Jacksonville. In the past I've sat in the press room, covering the goings on on behalf of the IMF
Following Friday's post about the release of important clinical trial data at the American Society of Clinical Oncology (ASCO) and European Hematology Association (EHA) meetings in June, Joe asked this: Pat, Looking forward to your take on ASCO. Do you have any sources of information for when and where the phase 3 Daratumumab clinical trials
There are a pair of important medical meetings just around the corner that should give us an idea about how well several of the new myeloma therapies are working in real live patients. The American Society of Clinical Oncology (ASCO) annual meeting is May 30th - June 3rd in Chicago, while the European Hematology Association
Incremental baby steps. I hope I haven't given the wrong impression about myeloma news coming out of Chicago at this year's American Society of Clinical Oncology (ASCO) meetings. I've been whining about how there hadn't been any big myeloma related news. That part is true. But there are hundreds of clinical trial results being presented
If you think about it, large numbers of patients have only been using Revlimid for six years or so; Velcade maybe seven or eight. So solid survival data is just starting to pop-up. Let me introduce you to a study, presented at ASCO, that should help shut-up the, "You need to transplant right away!" crowd.